GlassScriptPhysician profile
Mark F Jackson
NPI 1255470209
$225,162.76
in general payments reported to CMS, 2019-2025
10 companies · $5,265 in 2025
The $5,265 reported for 2025 was more than what 93% of Addiction Medicine (Anesthesiology) providers received nationally (typical 2025 total: $133).
See the full distribution for Addiction Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $41K · 2021: $34K · 2022: $56K · 2023: $23K · 2024: $4,000 · 2025: $5,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $10K · Food and Beverage: $560 · Travel and Lodging: $343 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,600.00 |
| Consulting Fee | $10,400.00 |
| Food and Beverage | $560.44 |
| Travel and Lodging | $343.17 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $189,635.57 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Eli Lilly and Company | $30,261.58 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $4,682.53 | 2019-2023 | Odomzo, Blu-U |
| Janssen Biotech, INC. | $184.14 | 2019-2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.00 | 2021-2022 | |
| Abbvie INC. | $126.30 | 2021 | |
| Merz North America, INC. | $45.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.14 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.13 | 2025 | Exparel, Iovera, Zilretta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.